Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Diabetes Mellitus, Type 1 Clinical Trials

A listing of Diabetes Mellitus, Type 1 medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (348) clinical trials

Doctors in your area are evaluating the safety and effectiveness of a study medication to find out if it has the potential to maintain beta cell (insulin producing) function in the pancreas of children and young adults who have type 1 diabetes.

Phase N/A

Children and young adults who have Type 1 Diabetes are invited to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

The maximum duration for GLP1-RA patients will be approximately 29 weeks: an up to 2 week screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or 9 day post-treatment safety followup period. Maximum duration for FRC patients will be approximately 55 weeks: an up to ...

Phase

This study will look at an investigational product as potential treatment for type 1 diabetes. This study will have 19 study visits over 30 to 35 weeks. Sixteen of the study visits will be 1 to 2 hours. Three of the study visits will be overnight and will last 18 ...

Phase N/A

The purpose of this study is to support the development of a questionnaire to better understand and assess patient experiences with using GLP-1 therapies for type 2 diabetes mellitus.

Phase N/A

The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1 diabetes mellitus (T1DM).

Phase N/A

The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1 diabetes mellitus (T1DM).

Phase N/A

To demonstrate equivalence of Gan & Lee Pharmaceuticals insulin glargine and Lantus® in terms of immunogenicity and efficacy Secondary Objectives: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26

Phase N/A

The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1 diabetes mellitus (T1DM).

Phase N/A

The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1 diabetes mellitus (T1DM).

Phase N/A